12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BAL101553: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.K. Phase I/II trial showed that 15-60 mg/m 2 IV BAL101553 on days 1, 8 and 15 of a 28-day cycle were well tolerated. The MTD...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >